GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2010

Bruker to Buy Certain Varian Chromatography Product Lines from Agilent

  • Bruker is acquiring Varian product lines from Agilent Technologies that Agilent had committed to divesting to obtain regulatory approval for its purchase of Varian. Bruker will gain Varian’s global inductively coupled plasma mass spectrometry (ICP-MS) instruments business located in Melbourne, the global laboratory gas chromatography (Lab GC) instruments business located in Middelburg, The Netherlands, and the global gas chromatography triple-quadrupole mass spectrometry (GC-QQQ) instruments business located in Walnut Creek, CA.

    Agilent and Bruker also intend to enter into transitional services and supply agreements to facilitate the uninterrupted delivery of these products and services to new and existing customers. After the closing of the acquisition, Bruker intends to continue to operate these businesses from facilities located in Victoria, Australia, The Netherlands, and Northern California. The company also expects to retain key management, R&D, operations, sales, and marketing as well as applications and service personnel in each of the businesses.

    “These three businesses offer an opportunity to leverage our existing strengths in the analytical instruments market,” notes Frank Laukien, Bruker president and CEO. “The three new product lines will form the core offerings in a newly established Bruker Chemical Analysis Division with an experienced and dedicated management team.”

    In July 2009, Agilent agreed to pay $1.5 billion in cash to take over Varian. The acquisition, which is expected to close by April 30, will bolster Agilent’s life science, environmental, energy, and materials offerings.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?